Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced today that it will host a live webcast on Wednesday, April 30th at 11:30 ...

CARLSBAD, Calif., April 16, 2025--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced today that it will host a live webcast on Wednesday, April 30th at 11:30 a.m. Eastern Time to discuss its ...

TD Cowen analyst Yaron Werber maintained a Buy rating on Ionis Pharmaceuticals (IONS – Research Report) today and set a price target of $59.00.

Ionis Pharmaceuticals IONS shares rallied 8.9% in the last trading session to close at $27.77. This move can be attributable to notable volume with a higher number of shares being traded than in a ...

Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $55.0, with a high estimate of $70.00 and a low estimate of $39.00. Observing a downward ...

Ionis Pharmaceuticals, Inc. engages in the development and commercialization of human therapeutic drugs using antisense technology. It operates through the Ionis Core and Akcea Therapeutics segments.

Learn more about whether Alvotech or Ionis Pharmaceuticals, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

Morgan Stanley lowered the firm’s price target on Ionis Pharmaceuticals (IONS) to $52 from $55 and keeps an Equal Weight rating on the shares.

Ionis Pharmaceuticals, Inc., a commercial-stage biotechnology company, provides RNA-targeted medicines in the United States. The company offers TRYNGOLZA reduces triglyceride levels in adults with ...

Learn more about whether Ionis Pharmaceuticals, Inc. or Moderna, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...